(S)-crizotinib,
ent-crizotinib,
1374356-45-2,
S-CRIZOTINIB,
3-[(1s)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Ylpyrazol-4-Yl)pyridin-2-Amine,
(S)-3-(1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY)-5-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE,
CHEMBL1825141,
CHEBI:77555,
3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine,
C21H22Cl2FN5O,
Tube712,
GTPL7581,
SCHEMBL14811801,
KTEIFNKAUNYNJU-LBPRGKRZSA-N,
2128AH,
BDBM50352564,
s7505,
ZINC35902488,
(S)-Crizotinib, >=98% (HPLC),
AKOS025401749,
NCGC00384190-02,
AC-25088,
HY-100549,
CS-0019694,
J3.637.461F,
A14291,
BRD-K40308497-001-02-0,
Q27467066,
(S)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine,
2-Pyridinamine, 3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-,
3-[(1S)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine,
VHS,
Crizotinib,
D03OZD,
CB12102,
A8802,
PF-02341066,
877399-52-5,